03:13 PM EST - ProMIS Neurosciences, Inc. : Announced the successful humanization of its lead product candidate for Alzheimer's disease, PMN310, a monoclonal antibody (mAb) targeting toxic prion-like forms of amyloid-beta oligomers. ProMIS Neurosciences, Inc.
shares T.PMN are trading unchanged at $0.25.
